640. Prospective Association of Serum Vitamin D Level with Sepsis-Mortality in Postmenopausal Women: Results From the Women’s Health Initiative

Paulette Pinzone, MD; Reema Qureshi, MD; Wilmer Salazar, MD; Mary Roberts, MS; Charles Eaton, MD, MS; Linda Snetselaar, PhD, RDN, LD; Meryl LeBoff, MD; Rini Ann Manson, MD, MPH; Ikako Kato, PhD; and Erin S LeBlanc, MD, MPH.

Backgrounds. Vitamin D deficiency has been studied in the critically ill, and has been associated with worse morbidity and mortality rates, especially in those admitted with sepsis. Sepsis is a major cause of ICU admissions and accounts for 250,000 deaths per year. Dihydroxyvitamin D can inhibit the production of interleukins, tumor necrosis factor and can also increase the expression of endogenous antimicrobial peptides. This study sought to assess if low serum concentrations of 25(OH)D were associated with higher sepsis mortality rates.

Methods. This is a prospective study composed of participants from the Women’s Health Initiative (WHI) in the Vitamin D/Calcium trial who have been followed for an average of 15 years. The analysis sample consists of participants who had 25(OH)D measured at baseline. Patients with kidney disease and self-reported cancer at enrollment were excluded. Vitamin D deficiency was defined as levels <20 ng/mL which was categorized into severe deficiency [25(OH)D] <12 ng/mL and mild deficiency [25(OH)D of 12–20 ng/mL]. A Cox proportional hazard model was used to study the association between serum Vitamin D and sepsis mortality.

Results. 10,814 participants were included in the study (mean age = 64.4 years). At baseline, 49.26% (n = 5,328) of the sample had vitamin D deficiency and of those who died from sepsis, 57.7% (n = 41) where found to be vitamin D deficient. We found statistically significant increased hazard ratios (HR) for sepsis mortality in mild (HR = 1.15; 95% CI 1.00–1.14) and severe vitamin D deficiency (HR = 1.18; 95% CI 1.02–1.31) in age adjusted and fully adjusted models (Table 1).

Conclusion. Vitamin D deficiency is associated with increased risk of sepsis mortality in postmenopausal women, which was seen in all ages. A clinical trial evaluating adequate intervention of Vitamin D supplementation in patients with sepsis is recommended to assess clinical significance.

Disclosures. All authors: No reported disclosures.

Table 1. Cox models for sepsis mortality (Hazard Ratio with 95% CI)

| Model | Vitamin D Level | Severe Deficiency | Mild Deficiency | No deficiency |
|-------|-----------------|-------------------|----------------|--------------|
| Model 1: Crude | 1.27 (1.17, 1.37) | 1.21 (1.13, 1.29) | 1.20 (1.08, 1.33) |
| Model 2: Age-adjusted | 1.24 (1.15, 1.34) | 1.20 (1.13, 1.29) | 1.19 (1.08, 1.32) |
| Model 2: Age + SES* | 1.24 (1.17, 1.32) | 1.21 (1.09, 1.34) | 1.19 (1.07, 1.31) |
| Model 2: Age + Behavioral variables** | 1.23 (1.19, 1.28) | 1.21 (1.09, 1.33) | 1.19 (1.07, 1.30) |

*Vitamin D levels ≤50 nmol/L: mild deficiency; 50–75 nmol/L: moderate deficiency; >75 nmol/L: severe deficiency
**Behavioral variables: smoking, daily exercise, alcohol intake, BMI, diet.

Infectious Diseases, University of Colorado Denver, Aurora, Colorado, 2Denver Public Health, Denver, Colorado, 3University of Alabama at Birmingham, Birmingham, Alabama, 4Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, University of Colorado Denver, Aurora, Colorado

Session: 65. Pathogenesis and Immune Response
Thursday, October 4, 2018: 12:30 PM

642. B- and T-Cell Responses to Pneumococcal Polysaccharide and Protein Vaccine Antibiotics in Recently Diagnosed HIV-1-Infected Patients

Lindsay K. Nicholson, MD; Vibha Jha, PhD; Edward M. Gardner, MD, MPH; Jeremy Rahalka, MD; Barret ES; Moon H. Nahm, MD; and Edward D. Sabin.

Backgrounds. Prevention of severe HIV-1-associated pneumococcal infections may be complicated by the limited magnitude and function of vaccine-induced antibodies. Responses to the T-independent pneumococcal capsular polysaccharide (PPS) + T-dependent diphteria toxoid (DT) protein conjugate vaccine (PCV-13) may be influenced by CD4+ T follicular helper (TFH) cells which provide specific help for B-cell differentiation.

Methods. We immunized 22 control and 19 newly diagnosed HIV-1-infected adults (median 610 CD4+ T cells/µL; range: 139–1,408) and 69,316 plasma HIV RNA (range 232–806,936) on ART for 1–4 months with PCV13. We measured (i) PPS-specific antibody-secreting cells (ASCs) by ELISPOT at Weeks 0 and 1, (ii) serum IgG to 11 PPS serotypes (ST) by multiplex ELISA, (iii) tonsils to four STs at Weeks 0 and 8, and (iv) numbers and activation (ICOS expression) of circulating TFH cells by flow cytometry at Weeks 0 and 1. Values were compared by ANOVA, paired and unpaired t and Mann–Whitney tests.

Results. The number of PPS-specific IgG, IgM and IgA ASC increased significantly from Weeks 0 to 1 post-PCV13 and to similar magnitude in both Controls and HIV+ subjects, returning to baseline by Week 8. Levels of serum PPS-specific IgG increased significantly from Weeks 0 to 8 for 10/11 vs. 7/11 ST in controls and HIV+ subjects, respectively. TFH cells by flow cytometry were upregulated on cells from Control but not HIV+ at Week 1. Moreover, levels of IL-12, a key regulatory molecule on TFH cells, were lower among HIV-1+ adults (P = .001). Consistent with these limited responses, a key regulatory molecule on TFH cells, elicit largely by T-dependent antigens (DT), was perhaps more recalcitrant HIV-1-associated T-cell defect.

Disclosures. All authors: No reported disclosures.

643. Coronary Artery Aneurysms Are Found on Blindly Read Echocardiograms From Febrile Patients with and Without Kawasaki Disease

From Febrile Patients with and Without Kawasaki Disease

Kunjil Desai, MD; Eden J Robinowitz, MD; Elizabeth Mitchell, MD; Denise Hayes, MD; Ayukt Tugettmur, MD; Elena Kwon, MD; Preeta Dhankantiw, MD; Nilanjana Misra, MBBS and Lorrie Rubin, MD, FIDSA; Pediatrics, Cohen Children's Medical Center, New Hyde Park, New York; Pediatric Cardiology, Cohen Children's Medical Center, New Hyde Park, New York, 2Pediatric Cardiology, Cohen Children's Medical Center of New York, Northwell Health, New Hyde Park, New York

Session: 65. Pathogenesis and Immune Response
Thursday, October 4, 2018: 12:30 PM

Backgrounds. In previous studies, our lab has characterized a number of highly mutated antibodies against structural epitopes of the human immunodeficiency virus (HIV) envelope protein. These antibodies were first isolated from long-term nonprogressors (LTNPs). We have previously mapped 6F5 to a novel structural epitope that encompasses areas in both heptad repeats of GP41, mapping to amino acids of 557, 654 and 657 of reference sequence HXB2. In these studies, three other antibodies that were <90% homologous to 6F5 also resolved amino acid 657. On sequence analysis, 6F5 and its relatives had the same gene usage and general structure. These similarities and the similar epitope mapping implied these were once distantly related to a single B-cell lineage. As fusion of the viral membrane to the target cell depends on these heptad repeat regions associating and forming a six-helix postfusion bundle, antibodies that can interfere in this may be highly useful.

Methods. See results.

Results. Because 6F5 maps to 557 and 654-657 which are widely separated on the gp41 structure, we explored if there was a differential binding to the postfusion six-helix bundle form. Two peptides (N36 and C34) each containing one of the heptad repeats can form the post-fusion six-helix bundle in vitro. On sandwich ELISA testing, 6F11 and 7B6 did not bind any form. Interestingly, 4E4 specifically captured both peptides alone, but not the six-helix-bundle and 6F5 only bound the six-helix-bundle but not the other peptide.

A small number of samples were obtained to assess the prevalence of these responses in LTNPs. Antibodies that compete 6F11 are much more prevalent in LTNPs than normal (75% vs. 20%). Functionally, we found that despite being mapped to a similar portion of GP41 (657), only 6F5 is shown to have significant ADCC activity, however relative 6F11 does not.

Conclusion. If targeting these epitopes correlates with the LTNP state, then these sites may be highly significant as targets of therapeutics or in vaccine strategies. Further studies on a larger cohort of LTNPs are ongoing. Additionally, deep sequencing of antibody sequences are being done to explore the development of structural epitope targeting by this family of antibodies.

Disclosures. All authors: No reported disclosures.